Abbonarsi

Prenatal antidepressant use and the implication of hypertensive disorders during pregnancy - 27/11/21

Doi : 10.1016/j.ajog.2021.06.003 
Lin-Ya Yang, MS, BPharm 1, Fang-Ju Lin, PhD 2, 3, 4, Aaron J. Katz, PharmD, PhD 5, I-Te Wang, MD, MS 6, Chung-Hsuen Wu, PhD 1, ⁎
1 School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan 
2 Graduate Institute of Clinical Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan 
3 School of Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan 
4 Department of Pharmacy, National Taiwan University Hospital, Taipei, Taiwan 
5 Departments of Population Health and Radiation Oncology, University of Kansas School of Medicine, Kansas City, KS 
6 Department of Obstetrics and Gynecology, Taipei Medical University Hospital, Taipei, Taiwan 

∗Corresponding author: Chung-Hsuen Wu, PhD.

Abstract

Background

Evidence for the association between prenatal antidepressant use and the development of hypertensive disorders of pregnancy is inconsistent. Previous studies have reported that antidepressant use during pregnancy increases the risk for gestational hypertension and preeclampsia, but the results of these studies are potentially confounded by important methodologic limitations. Furthermore, it remains unknown whether a higher cumulative dose of antidepressant increases the risk for hypertensive disorders of pregnancy.

Objective

This study aimed to investigate the association between prenatal antidepressant use and the risk for hypertensive disorders of pregnancy and the potential effect of a higher cumulative antidepressant dose.

Study Design

This retrospective cohort study used data from the Health and Welfare Database in Taiwan. Pregnant women with depression aged 18 to 49 years were enrolled as part of the study population. Prenatal antidepressant use was defined as at least 1 dispensing record of an antidepressant between the conception date and 20 weeks of gestation. Antidepressant users were further divided into groups according to the cumulative defined daily dose based on whether they took the defined daily dose for ≤10 weeks (low cumulative dose group ≤70 cumulative defined daily dose) or for >10 weeks (high cumulative dose group >70 cumulative defined daily dose). The primary outcome was hypertensive disorders of pregnancy defined as the diagnosis of either gestational hypertension or preeclampsia during the period from 20 weeks of gestation to delivery. Propensity score matching and stabilized inverse probability of treatment weighting were used to balance the confounders between the comparison groups. A robust Cox regression model was used to evaluate the association between exposure and outcome.

Results

A total of 5664 pregnant women with depression were included in the study (2832 antidepressant users matched to 2832 antidepressant nonusers). Prenatal antidepressant use was not associated with an increased risk for hypertensive disorders of pregnancy (adjusted hazard ratio, 0.89; 95% confidence interval, 0.67–1.18). However, among antidepressant users, the risk for hypertensive disorders of pregnancy was higher among women with a higher cumulative defined daily dose than among women with a lower cumulative defined daily dose (adjusted hazard ratio, 2.46; 95% confidence interval, 1.05–5.74).

Conclusion

No association was found between antidepressant use and the development of hypertensive disorders of pregnancy. However, women taking higher cumulative doses of antidepressants were at greater risk. More frequent or regular monitoring of blood pressure may be warranted in women on high cumulative doses of antidepressants.

Il testo completo di questo articolo è disponibile in PDF.

Key words : antidepressant, gestational hypertension, National Health Insurance Research Database, preeclampsia, pregnancy


Mappa


 The authors report no conflict of interest.
 This study was funded, in part, by research grants from the Ministry of Science and Technology, Taiwan (under grant numbers MOST 106-2320-B-038-018 and MOST 108-2320-B-038-041 to C-H.W.). The funders had no role in the study design, data collection and analysis, result interpretation, publication decision, or manuscript preparation.
 The data for this study were obtained from the Health and Welfare Database, which is provided by the Health and Welfare Data Science Center of the Department of Statistics under the Ministry of Health and Welfare, Taiwan. The interpretation and conclusions contained in this study do not represent those of the Health and Welfare Data Science Center.
 Cite this article as: Yang L-Y, Lin F-J, Katz AJ, et al. Prenatal antidepressant use and the implication of hypertensive disorders during pregnancy. Am J Obstet Gynecol 2021;225:672.e1-11.


© 2021  Elsevier Inc. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 225 - N° 6

P. 672.e1-672.e11 - dicembre 2021 Ritorno al numero
Articolo precedente Articolo precedente
  • Therapeutic concentration of ciprofloxacin and transfer across the human term placenta
  • Mia Noergaard, Per Bo Jensen, Ditte Resendal Gotfredsen, Thomas Bergholt, Jon Trærup Andersen, Line Mathiesen
| Articolo seguente Articolo seguente
  • Dynamic esophageal patency assessment: an effective method for prenatally diagnosing esophageal atresia
  • Eran Kassif, Tal Elkan Miller, Abraham Tsur, Yana Trozky, Tomer Gur, Hila De Castro, Efrat Hadi, Vered Yulzari, Alina Weissmann-Brenner, Baruch Messing, Rakefet Yoeli-Ullman, Roni Sharon, Shali Mazaki-Tovi, Reuven Achiron, Boaz Weisz, Tal Weissbach

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.